Strategy, regulation and opportunity for pharma, biotech and investors in rare diseases
The third annual World Orphan Drug Congress USA - North America's leading orphan drug conference
The World Orphan Drug Congress USA is the world’s leading orphan drug conference fostering partnerships and collaboration among industry, governments and patients. It is about expediting orphan drug development and articulating its value; from discovery to clinical development to licensure to manufacturing to launch to sustainability of supply, so manufacturers are guaranteed full and speedy reimbursement.
This year's congress will feature two conference days and one additional workshop day, consisting of four total workshops!
Register for the World Orphan Drug Congress USA now and learn:
- How to improve clinical development of orphan drugs
- How to optimize patient partnerships in rare disease
- How to achieve regulatory approval for orphan drugs
- How to ensure reimbursement for orphan drugs in a faster way
- How to exploit global trends and learn from recent successes in the field
- How to devise international strategies for improving orphan drug market access
- How to improve manufacturing and distribution of orphan drugs
- How to improve orphan drug business models and commercialization strategies
Last year's speakers included representatives from:
- Shire
- Genzyme
- Lundbeck
- NORD
- Parent Project Muscular Dystrophy
- Pfizer
- AstraZeneca
- Eli Lilly
- Novartis
The World Orphan Drug Congress USA focus:
- Current trends
- Global initiatives
- Research & Development
- Clinical trials
- Manufacturing
- Launching
- Sustainability
- Global patient access
- Reimbursement
Who should attend:
- Big pharma and biotech
- SME Biotech
- Academia, research institutes and NGOs
- Government and regulatory agencies
- Patient advocates
- Clinicians
- Communications consultants
- Reumbursement consultants
- CROs and CMOs
